A second look: MRI screening may spot hidden prostate cancers

NCT ID NCT07762911

Recruiting now Prevention Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study follows men who had a negative prostate cancer screening about five years ago. They will undergo a repeat MRI and PSA test to see if any clinically significant prostate cancers have developed. The goal is to learn whether repeat screening is valuable and how often it should be done. The findings could help reduce unnecessary biopsies while still catching dangerous cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biparametric magnetic resonance imaging (bpMRI) of the prostate
What this could lead to: If successful, this could establish an optimal interval for repeat MRI-based prostate cancer screening, reducing unnecessary biopsies while catching dangerous cancers early.
What could go wrong: The study is observational and relatively small, and the benefit of repeat screening may not be confirmed. MRI can also miss some cancers or lead to false alarms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

University Hospital Basel, Urology
RECRUITING

Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.